TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01802385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline 400mg/day for 2 weeks, then 200mg/day for 12 weeks, then tapered over 3 weeks.
Study: NCT03810183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet + Standard of Care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 6 weeks administered orally as a tablet + Standard of Care
Study: NCT03307174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study: NCT00971113

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sc-FOS and Sideritis euboea extract
Description: dietary supplement: jelly with 5g sc-FOS and 0.3g Sideritis euboea extract per daily portion for 30 days~placebo food: jelly with no sc-FOS and Sideritis euboea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sc-FOS and Sideritis euboea extract
Description: dietary supplement: jelly with 5g sc-FOS and 0.3g Sideritis euboea extract per daily portion for 30 days~placebo food: jelly with no sc-FOS and Sideritis euboea
Study: NCT05836480

Intervention type: PROCEDURE
Intervention: mitral valve repair
Description: conservative surgery to treat mitral regurgitation. A mitral valve plasty is performed according to the most appropriate technique

Intervention type: PROCEDURE
Intervention: mitral valve repair
Description: conservative surgery to treat mitral regurgitation. A mitral valve plasty is performed according to the most appropriate technique
Study: NCT00863707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study: NCT05002972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking group led by a community organizer
Description: Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
Study: NCT03095807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-1706 A
Description: Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously (s.c., under the skin)
Study: NCT03113045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: seated time
Description: Pt will be seated for a predetermined time period. All Patients will receive intrathecal bupivacaine and morphine.
Study: NCT03639168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide combined with cisplatin
Description: Chidamide combined with cisplatin
Study: NCT01867008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus CI422 Cochlear Implant with N6 Sound Processor
Study: NCT00049816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: 30 minutes/day, 3 times/week for 52 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling Exercise
Description: 30 minutes/day, 3 times/week for 52 weeks
Study: NCT00512590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation and Guided Imagery
Description: The intervention consisted of 3 relaxation and guided imagery audiotapes used in a proscribed order for 6 weeks and used in any order for weeks 7 through 10.~Protocol: Tape 1: Basic Relaxation used for weeks 1 and 2. Tape 2: Pleasant Scene Imagery to elicit sensory involvement for enhanced sense of overall well-being; used for weeks 3 and 4. Tape 3: End-State Imagery designed to facilitate improved symptom management; used for weeks 5 and 6. Any of the tapes used as often as desired but at least once daily for weeks 7 to 10.
Study: NCT01578772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: 80mg tablets po daily for 6 weeks
Study: NCT01837745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhTSH stimulation
Description: Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I131
Description: An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow up
Description: * 10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation~* 2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4)~* 3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 4 years (+/- 2 months) after randomization: a serum Tg/LT4~* 5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up
Description: * 10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation~* 2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4)~* 3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 4 years (+/- 2 months) after randomization: a serum Tg/LT4~* 5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4
Study: NCT03008044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FiberSense system
Description: A novel CGM system based on a FiberSense system placed through the dermis of the patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FiberSense system
Description: A novel CGM system based on a FiberSense system placed through the dermis of the patient.
Study: NCT02574585

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal cells transplantation
Description: Two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
Study: NCT04072029

Intervention type: PROCEDURE
Intervention: Phacoemulsification with intraocular lens implantation
Description: Phacoemulsification (2.2mm coaxial, viscoelastic shield, experienced surgeon) with intraocular lens implantation (acrylic hidrophobic)
Study: NCT00745303

Intervention type: PROCEDURE
Intervention: Tai Chi Cuan
Description: Tai Chi Cuan training for 3 months
Study: NCT03416439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: lifestyle intervention program carried out by trained professionals
Study: NCT03040232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: biomechanical assessment
Description: biomechanical and strength assessment of both groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biomechanical assessment
Description: biomechanical and strength assessment of both groups
Study: NCT04056208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pistachio
Description: Unsalted pistachios

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Advice and resources will be provided
Study: NCT04054830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voltaren Ophtha 1 mg/ml, GSK
Description: Voltaren Ophtha 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
Study: NCT01125631

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every 8 weeks (4 doses total)
Study: NCT00167167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Description: Certain immune cells in your donor's blood called lymphocytes have been shown to fight cancer after bone marrow transplantation. We plan to transfuse large numbers of donor's lymphocytes in the hope of activating the recipient's immune system to attack cancer.
Study: NCT04375280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Development of a screening algorithm designed to determine a dysmobility profile in patients with chronic illness.
Description: Firstly, volunteers will be invited to complete online questionnaires on a secure platform. The mobility assessment will be carried out initially (t1) and up to a maximum of 4 times (t1 to t4) as part of a day hospitalization. Questionnaires will be diverse (SF36, KOOS, HOOS, BROCKER, MNA, TAMPA, etc.) in order to assess several aspects that compose mobility.~Physical evaluations will include various validated tests (isokinetic strength measure, TUG, 6MWT, Berg Balance Scale, etc.)
Study: NCT00469105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Literacy/Numeracy oriented educational intervention
Description: Receives comprehensive literacy/num sensitive diabetes care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Receives standard diabetes disease management
Study: NCT03103984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss diet
Description: Weight loss diet composed of 30% lipids, 30% proteins and 40% carbohydrates.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss diet
Description: Weight loss diet composed of 30% lipids, 30% proteins and 40% carbohydrates.
Study: NCT04315350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin Liposome
Description: Curcumin is given together with prednisolone

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Prednisolone is given together with curcumin-placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Prednisolone-placebo is given together with curcumin-placebo
Study: NCT04054830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voltaren Ophtha 1 mg/ml, GSK
Description: Voltaren Ophtha 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monopex 1 mg/ml, Théa
Description: Monopex 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monopex 1 mg/ml, Théa
Description: Monopex 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
Study: NCT01741415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIDI

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SC
Study: NCT02118285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 IV on days -6 through -2 from NK cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: CD3-/CD19- selected NK cells administered by intraperitoneal (IP) infusion on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 at 6 million units/dose IP 3 times a week x 6 doses with the 1st dose given immediately after the NK cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB024360
Description: INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)
Study: NCT02687802

Intervention type: OTHER
Intervention: mechanical ventilation
Description: we will measure static resistance, compliance and intrinsic positive end-expiratory pressure (PEEP) and other variables as risk factors for asynchrony occurrence
Study: NCT00153426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: West Virginia WISEWOMAN
Description: Print-based tailored health communications and computer-based interactive nutrition program
Study: NCT04127617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Osteopathic treatment~Dural system:~L5-S1 decompression; sacred decompression among the iliacs; occipital-sphenoid approach; decongestion of occipital condyles~Fascial system:~fascial techniques in the abdominal region: right hypochondrium, epigastrium, left hypochondrium, right side, mesogastrium, left side, right iliac area, hypogastrium, left iliac area; relationship with corresponding vertebral levels (eg, hypogastrium); fibro scar adhesions treatment.~Biomechanical system:~diaphragm rebalancing with respect to anatomical insertions; passive mobilization of dysfunctional areas. Nursing education as described in Standard Treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nursing Educational Care
Description: Nursing education~* assessment of the best personal evacuation strategy concerning the quality of life, individual resources, and level of autonomy;~* assessment of the correct execution of the identified evacuation manoeuvre (digital stimulation, manual removal, reflex stimulation, transanal irrigation, use of micro-enemas or suppositories;~* identification of the best postural strategies during evacuation;~* nutrition and proper hydration education;~* education in completing the evacuation diary;~* colonic massage training;~* verification of the correct hiring of any previously prescribed laxative drugs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Educational Care
Description: Nursing education~* assessment of the best personal evacuation strategy concerning the quality of life, individual resources, and level of autonomy;~* assessment of the correct execution of the identified evacuation manoeuvre (digital stimulation, manual removal, reflex stimulation, transanal irrigation, use of micro-enemas or suppositories;~* identification of the best postural strategies during evacuation;~* nutrition and proper hydration education;~* education in completing the evacuation diary;~* colonic massage training;~* verification of the correct hiring of any previously prescribed laxative drugs.
Study: NCT01830517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine, Losartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Losartan
Study: NCT03720886

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhPTH（1-34） 28.2μg
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhPTH（1-34） 56.5μg
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide acetate(Teribone™)
Description: Administered by subcutaneous injection
Study: NCT03347643

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS with real stimulation
Description: tDCS is a non-invasive brain stimulation. Real stimulation includes 2mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS with sham stimulation
Description: Sham stimulation includes 0mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
Study: NCT03257748

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LED therapy
Description: The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
Study: NCT01542008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized Adherence Enhancement (CAE)
Description: CAE consists of the application of a series of up to four psychosocial treatment modules based upon a baseline evaluation of adherence vulnerabilities/needs. The standardized modules (Psychoeducation, Modified Motivational Enhancement Therapy, Communication with Providers, Medication Routines), are assigned based upon pre-established criteria designed to fit the needs of the patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: broadly-directed, non-individualized education (EDU)
Description: EDU will consist of 4 core in-person sessions using the patient work-book from the NIMH funded study, Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), and following the general educational format of the Collaborative Care control intervention in the STEP study. EDU addresses BD treatment broadly, including diagnosis and management, and the sessions will review the materials and allow time for questions as needed.
Study: NCT00863382

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Event Monitor
Description: Standard Event Monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sleuth Monitor
Description: Implantable Sleuth Recorder
Study: NCT02125890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: two doses of Tranexamic Acid will be given to patients with rupture abdominal aortic aneurysms
Study: NCT04217291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-004
Description: Take orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-004
Description: Take orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-004
Description: Take orally once a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SY-004 matching placebo
Description: Take orally once a day
Study: NCT04039724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0605 + HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0605 + HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1305
Study: NCT03754920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prolonged fasting
Description: Fasting for 5 days: Fasting with some fitness regimen, such as meditation and mild physical exercise;~Feeding for 3 days: Gradually distribute participants with rice flour, porridge and juice.
Study: NCT04501250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rinsulin NPH
Description: subcutaneous injection at a dose of 0.4 IU/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rinsulin NPH
Description: subcutaneous injection at a dose of 0.4 IU/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin NPH
Description: subcutaneous injection at a dose of 0.4 IU/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin NPH
Description: subcutaneous injection at a dose of 0.4 IU/kg
Study: NCT00480844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.
Study: NCT04254510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial relaxation technique
Description: * Before the intervention, the number of days of the last menstrual cycle of all participants, the number of painful days throughout the cycle, pain intensity values according to the Visual Analogue Scale will be recorded, and the scores will be recorded in the participants.~* Technique of direct relaxation of fascia of both psoas muscles to the participants in the myofascial relaxation group since the end of the last cycle, 90-120 sec. It will be applied by the physiotherapist twice a week.
Study: NCT02037893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipyrine and Benzocaine otic solution
Description: antipyrine 54 mg and benzocaine 14 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipyrine Otic Solution
Description: Antipyrine 54 mg and glycerine dehydrated to 1.0 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzocaine Otic Solution
Description: benzocaine 14 mg and glycerine dehydrated to 1.0 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Otic solution
Description: Placebo otic solution will be glycerin that is dehydrated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Otic solution
Description: Placebo otic solution will be glycerin that is dehydrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Otic solution
Description: Placebo otic solution will be glycerin that is dehydrated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Otic solution
Description: Placebo otic solution will be glycerin that is dehydrated
Study: NCT02587208

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastibell
Description: In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional sleeve
Description: In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
Study: NCT01784874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Vero Rabies Vaccine (VRVg) - Serum Free
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imovax® Rabies: inactivated rabies vaccine
Description: 1.0 mL, Intramuscular